New drug combo targets genetic weakness in tough cancers
NCT ID NCT07277413
Summary
This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Houston
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.